Literature DB >> 8153668

Immunotherapy of malignant gliomas.

K A Jaeckle1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8153668

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  7 in total

1.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism.

Authors:  Vladimir V Didenko; Hop N Ngo; Candace Minchew; David S Baskin
Journal:  J Neurosurg       Date:  2002-03       Impact factor: 5.115

3.  Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

Authors:  B Frankel; S L Longo; T C Ryken
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 4.  The expanding role of chemotherapy for pediatric supratentorial malignant gliomas.

Authors:  D C Lyden; W P Mason; J L Finlay
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 5.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07

Review 6.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

7.  Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors.

Authors:  Y Manome; P Y Wen; A Hershowitz; T Tanaka; B J Rollins; D W Kufe; H A Fine
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.